Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States

Cosmatos, Irene; Matcho, Amy; Weinstein, Rachel; Montgomery, Michael T.; Stang, Paul

doi:10.1016/j.jaad.2012.07.027

Cited by 167 publications

(76 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The average annual number of patients diagnosed with HS at all settings as determined here for the years 2007-2008, 50.7 per 100,000 person-years, is in close agreement with the 2007 prevalence rates (52.09, 95% CI 50.51-53.68 adjusted by sex or 51.02, 95% CI 48.59-53.46 adjusted by age, per 100,000 person-years) determined by Cosmatos et al [7] using a large database of insurance claims from throughout the US.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Diagnoses of Hidradenitis Suppurativa in the United States, 1979-2012

McMillan¹

2015

Skin Appendage Disord

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is rarely diagnosed in the United States. Delayed diagnosis is a significant problem in the management of HS. In the past decade, there has been an increase in HS research. To determine whether those efforts have led to an increase in diagnoses, an analysis of visits to physicians in the United States from 1979 to 2012 was performed, using National Center for Health Statistics (NCHS) databases. Patient visits to private physician offices, hospital outpatient departments, and emergency rooms were analyzed. An increase in visit rates at outpatient departments from 2003-2007 [6.3/100,000, 95% confidence interval (CI) 2.9-9.8] to 2008-2010 (30.4/100,000, 95% CI 13.9-46.9; p = 0.017) was found. Converting the data to estimated numbers of patients, a 7-fold increase in patients from 2002-2007 (2.5/100,000, 95% CI 1.4-3.6) to 2008-2010 (16.9/100,000, 95% CI 7.8-26.1; p = 0.003) was found. No significant increase in patient or patient visit rates were found when analyzing visits in the physician office setting or combined office and hospital settings. Localization of increased diagnosis to outpatient departments may reflect the recent increase in clinical research. NCHS data can be useful in monitoring rates of HS diagnosis as an outcome of increased awareness of the disease.

show abstract

Section: Discussionsupporting

confidence: 89%

“…There are no drugs approved for HS by the US Food and Drug Administration and no laboratory tests for its diagnosis. Database studies have shown that HS is rarely diagnosed in the United States [6,7,8,9]; however, the true prevalence of HS, which includes undiagnosed and untreated populations, is unknown [10]. …”

Section: Introductionmentioning

confidence: 99%

Diagnoses of Hidradenitis Suppurativa in the United States, 1979-2012

McMillan¹

2015

Skin Appendage Disord

View full text Add to dashboard Cite

show abstract

“…In contrast to the European studies, the prevalence in the USA has been estimated based on health insurance data only. Using this approach, the prevalence appears to be significantly lower (0.05%) [11]. The average incidence of HS in the Rochester health insurance database is 6.0 patients per 100,000 population per year with an increasing trend (from 4.0 patients per 100,000 population in 1968 to 10.00 patients per 100,000 population in 2008; Rochester, Minn., USA) [12].…”

Section: Epidemiologymentioning

confidence: 99%

Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation

Zouboulis¹,

Marmol²,

Mrowietz³

et al. 2015

Dermatology

273

251

View full text Add to dashboard Cite

Background: Hidradenitis suppurativa/acne inversa (HS) is a chronic, inflammatory, recurrent, debilitating disease, which inflicts a significant burden on patients and is associated with comorbid disorders, such as significantly reduced quality of life, depression, stigmatization, inactivity, working disability, impairment of sexual health and several cardiovascular risk factors. Aims/Methods: To implement an expert consensus on the diagnostic criteria, severity and classification assessment, and an assessment of anti-inflammatory treatment effectiveness based on current evidence. Results: This article provides criteria for diagnosis, severity assessment, classification and evaluation of HS patients. Conclusion: The provided criteria can be used as tools for the promotion of uniformity in HS evaluation and facilitation of early and timely identification and referral in the primary care setting and thorough and efficient evaluation in daily clinical practice.

show abstract

“…European studies estimated HS prevalence to be 1% in the general population [5,6] and 4% in young adult women [7], whereas epidemiological data from American surveys reported prevalence between 0.05 and 0.20% [8,9]. The discrepancies between European and American studies may be due to the employment of different study methodologies or diverse diagnostic criteria but may also reflect actual differences in prevalence/incidence of HS.…”

Section: Epidemiologymentioning

confidence: 99%

Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review

Scuderi

Monfrecola

Dessy

et al. 2017

Skin Appendage Disord

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease presenting with painful nodules, abscesses, sinus tracts, and scarring primarily affecting apocrine gland-rich intertriginous areas. HS prevalence ranges from 0.05 to 1%. The central pathogenic event in HS is believed to be the occlusion of the upper part of the folliculopilosebaceous unit, leading to the rupture of the sebofollicular canal with the consequent development of perifollicular lymphohistiocytic inflammation. The HS treatment choices are influenced by disease severity and its individual subjective impact, involving both medical and surgical interventions. However, given the chronic nature of HS, its destructive impact on social, working, and daily life of patients, its management is often frustrating for both the patient and physician. Hence, prompt and effective management strategies are urgently needed and a multidisciplinary approach is advocated. Therefore, in this article, we highlighted the main features of HS (clinical aspects, epidemiology, pathogenesis, diagnostic criteria, classifications, comorbidities, and treatments), so that awareness of this disease might be heightened in primary care physicians and surgeons, who may be the first health care providers to see patients with this disease owing to its characteristic clinical presentation (inflammatory nodules, abscesses, sinus tract, etc.).

show abstract

Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States

Cited by 167 publications

References 18 publications

Diagnoses of Hidradenitis Suppurativa in the United States, 1979-2012

Diagnoses of Hidradenitis Suppurativa in the United States, 1979-2012

Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation

Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review

Contact Info

Product

Resources

About